The management team are on their game and things are progressing well with data flow this quarter and likely FDA approval 2020. This is relatively de-risked as a bio stock given that have a product that is known to work with increasing revenue generation and further studies in the pipeline around nerve injury and tendon repair. This should see the SP head north during Q3. The next 6 months will be exciting
Ann: Appendix 4C - Quarterly, page-6
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $65.71K | 166.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1052 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 354895 | 8 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |